Can Volastra Therapeutics turn KIF18A inhibition into a pan-cancer precision oncology platform?

Volastra Therapeutics unveils AACR 2026 biomarker and combination data for KIF18A inhibitors. Read what this means for oncology development.

Volastra Therapeutics unveils AACR 2026 biomarker and combination data for KIF18A inhibitors. Read what this means for oncology development.